Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion here at the Asian Pacific Society of Cardiology (APSC) Congress 2018 in Taiwan last week.
Implementation of an electronic national early warning score information system may cut the rate of in-hospital cardiac arrest, as well as improve the rate of survival to discharge, as shown in a study presented at the Asian Pacific Society of Cardiology (APSC) Congress 2018.
Even in the absence of peripheral arterial disease, a lower ankle-brachial index is significantly associated with larger declines in cognitive function, according to a poster presented at the 2018 Congress of the Asian Pacific Society of Cardiology (APSC 2018) in Taipei, Taiwan.
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor is superior to ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C), with or without statin therapy, according to a study presented at the Asian Pacific Society of Cardiology Congress 2018 (APSC 2018) in Taipei, Taiwan. Additionally, PCSK9 inhibitor shows comparable safety profile.
Hepatitis C virus (HCV) infection negatively affects the 12-year mortality in patients following acute myocardial infarction (AMI), as reported in a study from Taiwan. This association is particularly pronounced among males and individuals with hypertension, with cirrhosis further increasing the long-term mortality rates.
The reduction of intraventricular flow energy loss (EL) through biventricular (BiV) pacing appears to be linked to a decrease in the plasma levels of brain natriuretic peptide (BNP), reports a poster presented at the recently concluded 2018 Congress of the Asian Pacific Society of Cardiology (APSC 2018) in Taipei, Taiwan.
Compared to Western populations, the prevalence rates of Brugada syndrome and of sudden unexplained nocturnal death syndrome (SUNDS) are higher in Asia, particularly in the Philippines, reports Dr Giselle Gervacio in the recently concluded 2018 Congress of the Asian Pacific Society of Cardiology (APSC 2018) in Taipei, Taiwan.
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Adding epoetin alfa (EA) to lenalidomide significantly helps achieve major erythroid response (MER) in patients with erythropoietin (Epo)-refractory, lower risk non-deletion 5q (non-del(5q)) myelodysplastic syndrome (MDS) compared with lenalidomide alone, according to the final results of the E2905* trial presented at ASH 2019.